Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled ‘A Phase 3 Study to ...

(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company pioneering innovative therapies for viral diseases, is pleased to announce significant progress in development of its ...

Pregnant individuals commonly reported hesitancy toward RSVpreF and nirsevimab, indicating the need for efforts to promote the safety and uptake of RSV immunization.

RSV hospitalization was associated with increased risk for new CVEs and worsening of preexisting cardiovascular conditions.

Older adults hospitalized for respiratory syncytial virus (RSV) face an elevated risk of developing heart failure and a dangerous heart rhythm problem, a Canadian study found.

GSK is taking to the airwaves to talk RSV, presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games.

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing a phase 1 vaccine candidate to expand its RSV pipeline beyond mRNA.

The "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV)" project initiated by WHO/GAP-f aims to systematically review the global R&D pipeline, clarify R&D priorities, and promote ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

As such, we do not know how effective the treatment is for young children in low-income countries where the rate of death from respiratory syncytial virus lung infection is higher. The current ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s Enflonsia.

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9.